GI societies: ‘Little or no data’ linking GLP-1 agonists to safety issues during endoscopy (Healio)

In response to concerns about the safety of sedation for patients taking glucagon-like peptide-1 (GLP-1) receptor agonists, major GI societies, including AGA, AASLD, ACG, ASGE, and NASPGHAN, have urged gastroenterologists to adhere to “best practices” during endoscopy procedures. While these medications have been associated with adverse GI events, the societies emphasized that there is “little or no data” regarding the risk of complications from aspiration during sedation, and the effects of discontinuing these drugs before upper gastrointestinal endoscopy remain uncertain.